Skip to main content
Prescribed Retatrutide

A data-forward readout of every published retatrutide trial — figures, endpoints, and the cardiometabolic signal in the numbers.

WHERE THE FACTS CAME FROM

Retatrutide References and Study Links

Each entry links to the study, so you can open the source yourself.

What the main human study sources let you check

Phase 1b is an early test in a small group. Phase 2 tests benefit and common harm.

Phase 3 uses larger groups before approval. These retatrutide references name each study and its source.

What the lab work and reviews add

These sources include lab pictures and reviews from 2024–2025. They help you grasp how retatrutide may work, while human studies show what happened to people.

  1. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. ↗
  2. Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet. 2023;402(10401):529-544. ↗
  3. Li W, Zhou Q, Cong Z, Yuan Q, Li W, Zhao F, Xu HE, Zhao LH, Yang D, Wang MW. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discovery. 2024;10:77. ↗
  4. Urva S, Coskun T, Loh MT, Du Y, Thomas MK, Gurbuz S, Haupt A, Benson CT, Hernandez-Illas M, D'Alessio DA, Milicevic Z. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400:1869-1881. ↗
  5. Sanyal AJ, Kaplan LM, Frias JP, Brouwers B, Wu Q, Thomas MK, Harris C, Schloot NC, Du Y, Mather KJ, Haupt A, Hartman ML. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024;30:2037-2048. ↗
  6. Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. Retatrutide — A Game Changer in Obesity Pharmacotherapy. Biomolecules. 2025;15:796. ↗
  7. Kokkorakis M, et al. Emerging pharmacotherapies for obesity: A systematic review. Pharmacological Reviews. 2025. ↗
  8. Kommu S, et al. The Effect of Triple-Hormone-Receptor Agonist Retatrutide, a Novel Medication for Weight Loss, on Cardiovascular Risk Factors. J Am Coll Cardiol. 2024. ↗
  9. Eli Lilly and Company. A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3). ClinicalTrials.gov NCT05882045. 2023. ↗
  10. Eli Lilly and Company. The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Function. ClinicalTrials.gov NCT06383390. 2024. ↗
  11. et al. Triple Agonism Based Therapies for Obesity. Curr Atheroscler Rep. 2025. ↗
  12. Bailey CJ, et al. Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities. Peptides. 2025. ↗
  13. Laroche ML, et al. Dysesthesia associated with GLP-1 agonist therapies: data-mining analysis and literature review. European Journal of Clinical Pharmacology. 2026. ↗
  14. et al. The First Triple Agonist for Antiobesity: Retatrutide. Clin Diabetes. 2024. ↗